Tumor necrosis factor-a (TNF-a) is a pro-inflammatory cytokine, mainly produced by activated monocytes and macrophages. Excessive production of TNF-a is believed to underlie the progression of many serious inflammatory diseases, such as rheumatoid arthritis (RA), Crohn's disease and psoriasis. 1, 2) Recent clinical data, obtained using chimeric TNF-a antibodies 3, 4) and soluble TNF-a receptor fusion proteins 5) in the treatment of RA, have confirmed the important role of TNF-a in these inflammatory conditions. These agents are generally well tolerated but have drawbacks relating to patient cost, efficiency of production, and administration by injection. Therefore, inflammation research has focused on the development of orally active small molecular inhibitors of cytokine release.
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A serine/threonine kinase termed p38 mitogen-activated protein (MAP) kinase is a member of the stress-activated protein kinases and is considered as an attractive target. The prototypical p38 MAP kinase inhibitor SB 203580 ( Fig. 1) showed inhibitory activity in vivo against pro-inflammatory cytokine production in both mice and rats, 6) and several novel structural classes of p38 MAP kinase inhibitors have been demonstrated to efficiently reduce cytokine levels. 7) Thus, the regulation of TNF-a via the inhibition of p38 MAP kinase is expected to have beneficial effects in the treatment of inflammatory diseases. Although the efforts to develop small molecule agents for p38 MAP kinase have not yet yielded an agent ready to market, several inhibitors are presently under investigation in human clinical trials.
We have previously reported that 4-phenyl-5-pyridyl-1,3-thiazole derivatives showed strong anti-inflammatory activities 8, 9) but the anti-inflammatory mechanism of these compounds was not well-known. In a continuing effort to elucidate the mechanism, we found that 2-amino-4-phenyl-5-pyridyl-1,3-thiazole derivatives had potent adenosine receptor antagonistic activity and phosphodiesterase inhibitory activity. 10) These receptors and enzymes are related to adenosine or adenosine-3,5-triphosphate (ATP), suggesting that 4-phenyl-5-pyridyl-1,3-thiazole derivatives mimic adenosine and its related substrates. Taking these results into consideration, we explored the 4-phenyl-5-pyridyl-1,3-thiazole template, including rarely reported 2-acetylaminothiazole compounds. Herein, we report the synthesis and biological activities of a novel series of 4-phenyl-5-pyridyl-1,3-thiazole derivatives as p38 MAP kinase inhibitors.
Chemistry
The general approach for the synthesis of 4,5-disubstituted 2-acetylamino-1,3-thiazoles 7 is outlined in Chart 1. The 1-benzoyl-2-methylaziridines 2 were prepared from the corresponding acid chloride and commercially available 2-methylaziridine according to the Schotten-Baumann procedure. The lithium anion of methylpyridine 3 was condensed with 1-benzoyl-2-methylaziridines 2 and the resulting ketones 4
were brominated to give a-bromoketones 5.
11) Condensation of 5 with thiourea afforded 1,3-thiazoles 6. Since the subsequent acetylation of 6 under various standard conditions (acetic anhydride or acetyl chloride with triethylamine, or the Schotten-Baumann procedure) was unsuccessful due to the low reactivity of the amino moiety, we used N,N-dimethyl-4-aminopyridine (DMAP) as a catalyst in the reaction with acetyl chloride in N,N-dimethylacetamide (DMA).
The 4,5-disubstituted 2-alkyl(aryl)-1,3-thiazoles 8 were prepared from a-bromoketones 5 and thioamides 13 (Chart 2), which were prepared from the corresponding nitriles according to a process described in the previous report.
12) The cyclization reaction under previous condition using triethylamine as a base gave 8 in low to moderate yields, but an improvement in yield was achieved when no base was used. However, even under these conditions, the cyclization reaction of 5 and thioacetoamide 8c proceeded with low yield (20%) and ketone 4 was the major product obtained. Sulfide 8i was converted into the corresponding sulfoxide 9 on treatment with potassium peroxodisulfate in aqueous acetic acid.
13) The sulfonyl derivatives 10a and 10b were synthesized by oxidization of the corresponding sulfide 8i or 8k using 2 equivalents of m-chloroperbenzoic acid (mCPBA) in N,N-dimethylformamide (DMF). Saponification of 8j provided the corresponding carboxylic acid 11. Thiazole 8a was oxidized with mCPBA in DMF to afford N-oxide 12. All the synthesized thiazoles are listed in Table 1 .
Results and Discussion
The p38 MAP kinase inhibitory activities of 1,3-thiazole derivatives are shown in Table 2 . Firstly, the structure-activity relationship (SAR) around the pyridine ring at the 5-position of the thiazole nucleus was evaluated with 7a-c and 12. The 2-and 3-pyridyl derivatives 7c and 7b led to a drastic loss in activity, indicating that the 4-pyridyl group is essential for inhibitory activity. The diminished potency of N-oxide 12 indicated the importance of the nitrogen atom of the 4-pyridyl moiety as a hydrogen bond acceptor. According to the previous X-ray crystallographic data, the nitrogen atom seems to form a crucial hydrogen bond with the backbone NH of Met 109 in the enzyme. [14] [15] [16] Next, we focused on the SAR around the phenyl ring at 4-position. The bulky substituents, for example 4-tert-butyl (7m), had weak activity but the small substituents, such as 4-methyl (7f) or 4-chloro (7i) were tolerated. The introduction of substituents at the 2-position of the phenyl ring led to considerably less active compounds (7e, h, k). In addition, 3-chloro (7j) showed superior activity to 3-methoxy (7d) or 3-fluoro (7l). These results suggested that the steric requirement is a more important factor than the electronic factor. The most interesting compound in these 2-acetylaminothiazoles was the 3-methyl derivative 7g. Based on these results, we selected the 3-methyl group as a favorable substituent on the phenyl ring for the next SAR study around the 2-position of the thiazole.
The 2-amino derivative 6g can also provide good inhibitory affinity as seen with the acetyl amino compound 7g. The lower alkyl substituents (8a-c) were tolerated and the ethyl derivative 8a was the most potent in this series. The 2-phenyl analogue 8d did not result in improved activity. However, the introduction of substituents on the phenyl ring (8e-i) enhanced the potency. The compound 8g with a methyl group at the 4-position was more active than 2-methylphenyl (8e) or 3-methylphenyl (8f).
To evaluate the role of the substituent on the 2-phenyl ring, we examined a docking study between 10b and p38 MAP kinase using the DOCK program based on the X-ray crystal structure of the complex between SB 203580 and p38 MAP kinase.
15) The result of this study, as shown in Fig. 2 , suggested that the 4-methylsulfonylphenyl ring of 10b could form p-p staking interaction with Tyr 35 of the enzyme and an appropriate substituent on the phenyl ring would have the potency to derive additional contact with Arg 173 of the enzyme. The potency of sulfoxide 9 and sulfone 10a compared to sulfide 8i strongly supported the validity of this further contribution to binding potency. The phenol analogue 8h retained potent activity, while carboxylic acid analogue 11 resulted in decreased activity.
These compounds were further evaluated for their inhibitory activity by the lipopolysaccharide (LPS)-stimulated TNF-a release assay using the THP-1 cell for secondary screening (Table 2 ). There was no outstanding difference in p38 MAP kinase inhibitory activity between compounds bearing methoxy (7a, d) or chloro (7i, j) substituents. However, in this cell-based assay, compounds 7a and 7i with substituents at 4-position on the phenyl ring showed 5-fold and 22-fold more potency than 7d and 7j with substituents at 3-position, respectively. On the other hand, the 3-methyl analogue 7g exhibited improved activity compared to the 4-methyl derivative 7f, suggesting that methyl analogues produce a significantly different SAR.
To investigate the structural requirement of 4-(3-methylphenyl)thiazole derivatives in more detail, compounds with various substituents at 2 position of the thiazole ring were further profiled for their ability to inhibit TNF-a production. The amino (6g), which had strong inhibitory activity against p38 MAP kinase, showed less activity than 2-acetylamino (7g). Lower-alkyl substituents, such as methyl (8c) or ethyl (8a), were well tolerated, but tert-butyl (8b) and phenyl (8d) gave less activity. Little difference was observed in the series of 2-phenyl (8e-g). Although phenol (8h) was the most potent p38 MAP kinase inhibitor in this series, sulfoxide (9) and sulfone (10a) were much better tolerated than 8h in the cellular assay. It seemed that the hydrophobic substituents at 2-positon, such as methyl or ethyl, or less polar substituents, such as sulfinyl or sulfonyl, were superior to polar substituents, such as amino and phenol, in the cellular assay.
Based on p38 MAP kinase inhibition, TNF-a release assay results and the structural features, the three compounds, 2-acetamide (7g), 2-sulfonylphenyl derivatives 10a and 10b, were selected for the in vivo assay (Table 3) . Compound 7g inhibited TNF-a production by 43% while 10b was still more effective with 67% inhibition. Compound 10a showed no activity in this model at 10 mg/kg. These data suggest that the fluoro group has greater in vivo efficacy than the methyl group. We therefore examined the mouse plasma concentration after oral administration of 7g and 10b (Table  3 ). These two compounds demonstrated good results and compound 10b in particular had a more favorable pharmacokinetic (PK) profile in mice. Although the Novartis group has reported that pyridylthiazole has no activity in in vivo LPS mice, 17) these compounds showed significant anti-TNF-a activity in vivo and good oral absorption. In our effort to obtain an orally active p38 MAP kinase inhibitor, compounds 7g and 10b provided evidence of the potency of thiazole nucleus.
To evaluate the in vivo potency of p38 MAP kinase inhibitor as an anti-RA drug, compound 10b (10-50 mg/kg; p.o.) was tested in an anti-collagen (anti-CII) monoclonal antibody (mAb)-induced arthritis mouse model, as shown in Fig. 3 . In this mouse model, severe arthritis occurs about 24 h after LPS injection and persists for more than 21 d. 18) Treat- 
Conclusion
A series of novel thiazole analogues possessing potent in vitro inhibitory activity against p38 MAP kinase has been identified. The introduction of various substituents onto the phenyl ring and 2-position of the thiazole ring produced inhibitors with increased in vitro potency while maintaining excellent potency in the cellular assay. The potent analogue 10b inhibited p38 MAP kinase with an IC 50 of 51 nM and TNF-a production by 67% in mice at 10 mg/kg. This compound also displayed a significant ameliorative effect on the mouse anti-CII mAb-induced arthritis model (MED: 30 mg/kg; p.o.). The excellent in vitro and in vivo potency of this series warrants further investigation in more advanced analogues for the treatment of inflammatory diseases.
Experimental
General Melting points were determined on Yanagimoto micro melting point apparatus or Büche B-545 and are uncorrected.
1 H-NMR spectra were recorded on a Varian Gemini-200 (200 MHz) spectrometer, with tetramethylsilane as the internal standard. TLC analyses were carried out on Merck Kieselgel 60 F 254 plates. Elemental analyses were carried out by Takeda Analytical Laboratories, Ltd., and are within Ϯ0.4% of the theoretical values unless otherwise noted. Tetrahydrofuran (THF) was distilled over calcium hydride before use and other solvents and reagents were used without purification. Extracted solutions were dried over anhydrous Na 2 SO 4 unless otherwise noted and concentration of the organic solution was carried out under reduced pressure. Chromatographic purification was carried out on silica gel columns (Kieselgel 60, 0.063-0.22 mm, Merck) unless otherwise noted. The yields reported are not optimized.
1-(4-Methoxybenzoyl)-2-methylaziridine (2a)
A solution of 2-methylaziridine (50.5 ml, 0.645 mol) in diethyl ether (325 ml) was added to a 2 N aqueous sodium hydroxide (325 ml). This mixture was cooled to 0°C and 4-methoxybenzoyl chloride (100 g, 0.586 mol) was added dropwise to the mixture. After the addition, the mixture was further stirred for 1 h at 0°C. The organic phase was separated and the aqueous phase was extracted with ethyl ether. The combined organic phase was dried, and concentrated to afford 112 g (yield quant.) of 2a as 
1-(4-Methoxyphenyl)-2-(4-pyridyl)ethanone (4a)
Under argon atmosphere, a solution of diisopropylamine (46.3 ml) in THF (300 ml) was cooled to Ϫ78°C and a solution of 1.6 M n-butyllithium in hexane (208 ml) was added dropwise to the solution. After addition, the solution was stirred for 10 min and a solution of 4-methylpyridine (3) (28.3 ml) in THF (30 ml) was added dropwise to the LDA solution. The reaction mixture was allowed to warm up to Ϫ10°C and stirred for 20 min. The resulting mixture was cooled to Ϫ78°C and a solution of 2a (57.4 g) in THF (30 ml) was added dropwise to the mixture. After addition, the mixture was stirred for 1 h at Ϫ78°C, and then the reaction mixture was allowed to warm to room temperature. Water (300 ml) was added to the mixture and the organic phase was separated. The aqueous phase was extracted with ethyl acetate and the combined organic phases were dried and concentrated to give a crude crystal. This was recrystallized from ethyl acetate to afford 36.5 g (yield 54%) of 4a as a solid, mp 103-104°C,Vol. 53, No. 4 prepared 2-Bromo-1-(4-methoxyphenyl)-2-(4-pyridyl)ethanone Hydrobromide (5a) Bromine (1.6 ml, 31 mmol) was added dropwise to a solution of 4a (7.0 g, 31 mmol) in acetic acid (30 ml) and the mixture was stirred for 3 h at 80°C. The solvent was removed in vacuo and ethyl acetate was added to the residue. The resulting crystal was collected by filtration and washed with ethyl acetate to afford 11 g (yield 93%) of 5a as a solid, 1 
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2-Bromo-1-(3-methoxyphenyl)-2-(4-pyridyl)ethanone Hydrobromide (5d)
This compound was prepared from 4d as described in the synthesis of 5a as a crude oil and this compound was used for the next reaction without further purification.
2-Bromo-1-(2-methoxyphenyl)-2-(4-pyridyl)ethanone Hydrobromide (5e)
This compound was prepared from 4e as described in the synthesis of 5a as a solid, yield 57%, 1 
2-Bromo-1-(4-fluorophenyl)-2-(4-pyridyl)ethanone Hydrobromide (5l)
This compound was prepared from 4l as described in the synthesis of 5a as a solid, yield 81%, [4-(4-Methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (6a) Thiourea (2.2 g, 31 mmol) was added to a mixture of 5a (11 g, 28 mmol) in acetonitrile (170 ml), and then triethylamine (4.1 ml, 30 mmol) was added to the mixture. The resulting solution was refluxed for 3 h. The solvent was removed in vacuo and aqueous sodium hydrogen carbonate was added to the residue. The precipitate was collected by filtration and the resulting solid was washed with water and then ether. The crude crystal was recrystallized from ethanol to afford 5.5 g (yield 68%) of 6a as a solid, mp 282-284°C, 4-(2-Methoxyphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine (6e) This compound was prepared from 5e as described in the synthesis of 6a as a solid, yield 61%, mp 213-215°C (ethanol), 1 To a solution of 8a (2.8 g, 10 mmol) in DMF (50 ml) was added mCPBA (3.0 g, 12 mmol) at 0°C and the resulting mixture was stirred at room temperature for 14 h. Aqueous sodium hydrogen carbonate was added to the reaction mixture and extracted with ethyl acetate. The extracts were washed with brine, dried, and concentrated to give a solid. The crude crystal was washed with hexane to afford 2.2 g (yield 74%) of 12 as a solid, mp 143-144°C, 1 
